



Heart House
Roundtables

CARDIOVASCULAR CLINICAL RESEARCH IN THE COVID-19 ERA

FRIDAY, MAY 29



The emergence of COVID-19 has forced clinical researchers to endure major setbacks related to existing academic and industry-sponsored clinical trials.

Recognizing these constraints, what can be done to address these challenges, from patient enrollment, to regulatory constraints and interpretation of outcome data? Moving forward, how can the American College of Cardiology (ACC) lead the change in research designs that bring us innovative and rapid information collection, without sacrificing quality, and ultimately implementing evidence-based guidelines into everyday practice?

The CV Clinical Research in the COVID-19 Era Roundtable will virtually convene a group of leading clinical experts to better understand the pandemic's implications for on-going and future CV research. Discussions will be used to inform guidance that supports global efforts for mitigating the effects of the COVID-19 on research and help prioritize potential research questions related to its intersection with CV-related disease and risk factors.

HEART HOUSE ROUNDTABLES

The Heart House Roundtables explore the practical issues that clinicians and patients face every day within high-value clinical areas. Roundtables gather a diverse group of experts representing a wide variety of professional societies relevant to a specific topic, as well as other key stakeholders such as patients, federal agencies, health plans, integrated health systems and others as identified. The diversity of expertise is critical to the success of the roundtables, which provide a valuable forum for interactive and facilitated discussion on important issues. These meetings are designed to optimize in-depth discussion that not only identifies and clarifies the issues, but also allows participants the opportunity to brainstorm possible solutions.

For more information, visit [ACC.org/HeartHouseRoundtables](https://www.acc.org/HeartHouseRoundtables).

THE ACC COMMITMENT TO COVID-19 AND CARDIOVASCULAR HEALTH

The ACC is committed to rapidly responding to COVID-19 and the very real challenges it poses to CV health by bringing together multiple stakeholders to provide important clinical guidance, enduring educational resources and more.

Since the outbreak, the ACC has become the “go-to” source for clinical information related to COVID-19 and CV disease with its online **COVID-19 Hub**. This hub is a cross-College collaborative effort, drawing on the expertise and contributions of a wide range of ACC committees, councils, sections, *JACC Journals*, and individual experts.

As the COVID-19 pandemic continues, the ACC is playing a critical role in commissioning, organizing, and disseminating clinical guidance to cardiovascular clinicians and other health care workers worldwide. This work will only continue, with the goal of learning from today in order to prepare for a better tomorrow.

For more information, visit [ACC.org/COVID19](https://www.acc.org/COVID19).



AGENDA

Friday, May 29, 2020

10:00 a.m.	WELCOME <i>Athena Poppas, MD, FACC; ACC President</i>
10:05 a.m.	Overview of Roundtable and Introductions <i>James L. Januzzi, Jr., MD, FACC and Harlan M. Krumholz, MD, SM, FACC; Co-Chairs</i>
10:20 a.m.	SESSION 1: THE IMMEDIATE IMPACT OF COVID-19 ON CV RESEARCH: SUPPORTING THE RESEARCH COMMUNITY DURING A PANDEMIC <ul style="list-style-type: none">The Immediate Impact of COVID-19 on Clinical Research: A Real-World Case Example <i>Javed Butler, MD, MPH, MBA, FACC</i>Interactive Breakout Sessions (45 minutes) Goal: Gather recommendations to support future guidance regarding on-going clinical trials to address challenges presented by the COVID-19 pandemic.Report Back to Full Group (30 minutes)Recap from Co-Chairs (5 minutes)
11:55 a.m.	BREAK
12:00 p.m.	SESSION 2: THE INTERSECTION OF CV DISEASE AND COVID-19: PAVING THE WAY FOR FUTURE CLINICAL RESEARCH OPPORTUNITIES <ul style="list-style-type: none">COVID-19 and Beyond: ACC and Clinical Research <i>John S. Rumsfeld, MD, PhD, FACC</i>Interactive Breakout Sessions (45 minutes) Goal: Identify ways to leverage key takeaways from the COVID-19 pandemic and its intersection with CV disease to inform future research designs, operations, and knowledge generation.Report Back to Full Group (30 minutes)Recap from Co-Chairs (5 minutes)
1:35 p.m.	Q&A AND RECAP SESSION <ul style="list-style-type: none">Address Questions from WebEx Chat and Prioritize Next Steps <i>James L. Januzzi, Jr., MD, FACC and Harlan M. Krumholz, MD, SM, FACC; Co-Chairs</i>
2:00 p.m.	ADJOURN

On behalf of the ACC, we are thankful to the members of the
CV Clinical Research in the COVID-19 Era Roundtable Planning Committee
for their hard work and guidance in planning and
executing this first virtual Roundtable.

ACC CARDIOVASCULAR CLINICAL RESEARCH IN THE COVID-19 ERA ROUNDTABLE PLANNING COMMITTEE



**James L. Januzzi, Jr., MD, FACC
(Co-Chair)**

Hutter Family Professor of Medicine
Harvard Medical School
Director, Dennis and Marilyn Barry
Fellowship in Cardiology Research
Senior Cardiometabolic Faculty
Baim Institute for Clinical Research
Trustee, American College of
Cardiology



**Harlan M. Krumholz, MD, SM, FACC
(Co-Chair)**

Harold H. Hines, Jr.
Professor of Medicine
Professor in the Institute for Social
and Policy Studies
Director of the Yale New Haven
Hospital Center for Outcomes
Research and Evaluation (CORE)
Yale University



Ty J. Gluckman, MD, FACC

Chair, ACC Solution Set Oversight
Committee
Medical Director, Center for
Cardiovascular Analytics, Research,
and Data Science (CARDS)
Providence Heart Institute
Providence St. Joseph Health



**Thomas M. Maddox,
MD, MSc, FACC**

Chair, ACC Science & Quality Committee
Executive Director of the Healthcare
Innovation Lab
BJC HealthCare and Washington
University School of Medicine
Professor of Medicine
Washington University School of
Medicine



Eric C. Stecker, MD, MPH, FACC

Associate Professor of Medicine
Division of Cardiovascular Medicine
Oregon Health & Science University,
School of Medicine